Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Bullish +75

Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization

AI-generated analysis

🚀 Charles River introduces rapid cell banking programs that reduce production timelines by 40% compared to the industry standard of 20 weeks.

🧬 The new platform combines rapid cell bank packages with Next-Generation Sequencing (NGS) for comprehensive end-to-end characterization services.

🦠 Charles River utilizes rapid microbiological methods including Celsis ATP-Bioluminescence technology and real-time PCR to replace traditional testing and accelerate release timelines.

🏛️ The company's solutions are designed to meet stringent global regulatory expectations from the FDA, EMA, and ICH guidelines for accuracy and compliance.

🤝 Charles River acquired Pathoquest to integrate advanced NGS expertise and technology platforms into its existing quality control testing capabilities.

🔬 The iDTECT platform leverages NGS to provide reliable in vitro characterization services that ensure high-quality products are delivered efficiently.

⚖️ These offerings support the company's commitment to the 3Rs by developing alternative methods that reduce reliance on animal testing while supporting efficient product development.

Bullish Signals
  • Charles River Laboratories has introduced rapid cell banking programs that achieve a 40% reduction in cell bank production timelines compared to the industry standard of 20 weeks.
  • The company's new platform combines rapid cell banking with Next-Generation Sequencing (NGS) to significantly accelerate release timelines for biopharmaceutical and advanced therapy developers.
  • Charles River offers rapid microbiological methods using Celsis ATP-Bioluminescence technology and real-time PCR that replace traditional compendial testing, resulting in faster pre-bank and release testing timelines.
  • The acquisition of Pathoquest strengthens Charles River's capabilities in NGS solutions for in vitro characterization and quality control testing of biopharmaceutical products.
  • Charles River delivers a comprehensive, end-to-end solution that enhances product quality, safety, and regulatory readiness while reducing overall development timelines for clients.
Full Analysis
Charles River Laboratories International, Inc. has launched new rapid cell banking programs that integrate Next-Generation Sequencing (NGS) to accelerate release timelines for biopharmaceutical and advanced therapy developers. This comprehensive end-to-end solution is designed to enhance product quality, safety, and regulatory readiness while significantly reducing overall development durations. The platform achieves a 40% reduction in cell bank production timelines compared to the industry standard of 20 weeks. By combining rapid cell banking packages with advanced NGS characterization, Charles River enables clients to reach critical milestones faster and bring innovative treatments to patients sooner without compromising on safety or compliance. To support these accelerated timelines, Charles River employs rapid microbiological methods (RMM) for microbial detection using Celsis ATP-Bioluminescence technology and real-time PCR for mycoplasma detection. These automated, objective technologies replace traditional compendial testing, resulting in faster pre-bank and release testing phases that align with global regulatory expectations from the FDA and EMA. The company further strengthens its capabilities through the integration of Pathoquest, a leader in NGS solutions for in vitro characterization. This acquisition allows Charles River to leverage advanced sequencing-based testing services via its iDTECT platform, ensuring high-quality products are delivered efficiently while maintaining strict CGMP compliance and meeting international regulatory guidance such as ICH Q5A and Q5B.